drugset / Trial / NCT06705998
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
RandomizedSequentialTriple-blindOther
Summary
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study. Part A: randomised, double-blind, placebo-controlled, single ascending dose study. Part B: open label, multiple ascending dose study.
Timeline
- Start
- 2024-12-04
- Primary completion
- 2026-05-15
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAR502 | Unknown | 3 mg | Oral |
| Subject | BAR502 | Unknown | 10 mg | Oral |
| Subject | BAR502 | Unknown | 30 mg | Oral |
| Subject | BAR502 | Unknown | 60 mg | Oral |